Download PDF

1. Company Snapshot

1.a. Company Description

MEI Pharma, Inc., a late-stage pharmaceutical company, focuses on the development and commercialization of various therapies for the treatment of cancer.The company develops Zandelisib, an oral phosphatidylinositol 3-kinase delta inhibitor that is in Phase III clinical trial for the treatment of patients with relapsed/refractory follicular lymphoma, as well as in Phase Ib multi-arm trial to treat B-cell malignancies; and Voruciclib, an oral cyclin-dependent kinase 9 inhibitor, which is in Phase Ib clinical trial for acute myeloid leukemia and B-cell malignancies.It also develops ME-344, a mitochondrial inhibitor targeting the oxidative phosphorylation complex that is in Phase I clinical trial for the treatment of human epidermal growth factor receptor 2 negative breast cancer; and Pracinostat, an oral available histone deacetylase inhibitor, which is in Phase II clinical trial to treat patients with myelodysplastic syndrome.


MEI Pharma, Inc.has a license, development, and commercialization agreement with Kyowa Kirin Company; a clinical collaboration with BeiGene, Ltd.; a license, development, manufacturing, and commercialization agreement with Helsinn Healthcare SA; and a license agreement with Presage Biosciences, Inc.The company was formerly known as Marshall Edwards, Inc.


and changed its name to MEI Pharma, Inc.in July 2012.MEI Pharma, Inc.


was incorporated in 2000 and is headquartered in San Diego, California.

Show Full description

1.b. Last Insights on MEIP

MEI Pharma's recent performance was driven by a significant private placement of $100 million, which will be used to initiate a Litecoin treasury strategy, making it the first and only publicly traded LTC holder on a national exchange. This strategic move is expected to provide a new revenue stream and diversify the company's assets. Additionally, the company's recent announcement has sparked investor interest, resulting in a substantial increase in trading volume.

1.c. Company Highlights

2. Transcript Summary

Unfortunately this company is not part of our coverage yet. But as part of your subscription plan you can request it by clicking just below and we'll process.

Request Coverage

3. NewsRoom

Card image cap

MEI Pharma, Inc. Rebrands as Lite Strategy, Inc., Adopts New NASDAQ Ticker ‘LITS'

Sep -10

Source: businesswire.com

Card image cap

BTC digital asset field continues to exert its strength, HASHJ launches Bitcoin cloud mining platform with "capital + technology" dual-driven mode

Jul -25

Source: thenewswire.com

Card image cap

MEI Pharma Announces Closing of $100,000,000 Private Placement to Initiate Litecoin Treasury Strategy, Becoming First and Only Publicly Traded LTC Holder on a National Exchange

Jul -22

Source: businesswire.com

Card image cap

Why Is MEI Pharma Stock Soaring On Friday?

Jul -18

Source: benzinga.com

Card image cap

MEI Pharma Announces $100,000,000 Private Placement to Initiate Litecoin Treasury Strategy, Becoming First and Only Publicly Traded LTC Holder on a National Exchange

Jul -18

Source: businesswire.com

Card image cap

MEI Pharma Reports Third Quarter Fiscal Year 2025 Cash Position

May -13

Source: businesswire.com

Card image cap

MEI Pharma Reports Second Quarter Fiscal Year 2025 Cash Position

Feb -12

Source: businesswire.com

Card image cap

MEI Pharma Reports Fiscal Year End 2024 Cash Position

Sep -19

Source: businesswire.com

4. Business Breakdown

4.a. Revenues by Country

4.b. Revenues by Segment

5. Expected revenues mid-term growth (9.27%)

6. Segments

Pharmaceutical Compounds

Expected Growth: 9.27%

MEI Pharma's 9.27% growth in Pharmaceutical Compounds is driven by increasing demand for cancer treatments, strategic partnerships, and a strong pipeline of novel oncology candidates. Additionally, the company's focus on precision medicine and targeted therapies has led to increased adoption and revenue growth.

7. Detailed Products

Pracinostat

A oral inhibitor of the enzyme histone deacetylase (HDAC) for the treatment of advanced hematologic malignancies

ME-344

A mitochondrial inhibitor of complex I for the treatment of solid tumors

ME-401

A PI3K delta inhibitor for the treatment of B-cell malignancies

Zandelisib

A PI3K delta inhibitor for the treatment of B-cell malignancies

8. MEI Pharma, Inc.'s Porter Forces

Forces Ranking

Threat Of Substitutes

MEI Pharma, Inc. operates in a niche market with limited substitutes, reducing the threat of substitutes.

Bargaining Power Of Customers

MEI Pharma, Inc. has a diverse customer base, reducing the bargaining power of individual customers.

Bargaining Power Of Suppliers

MEI Pharma, Inc. relies on a few key suppliers, giving them some bargaining power, but the company's size and reputation mitigate this threat.

Threat Of New Entrants

The pharmaceutical industry is highly competitive, and new entrants can easily disrupt the market, posing a significant threat to MEI Pharma, Inc.

Intensity Of Rivalry

The pharmaceutical industry is highly competitive, with many established players, leading to intense rivalry and competition for market share.

9. SWOT Analysis

Strength

Weaknesses

Opportunities

Threats

10. Capital Structure

10.a. Balance Sheet

10.b. Weighted Average Cost of capital

Value
Debt Weight 34.08%
Debt Cost 3.95%
Equity Weight 65.92%
Equity Cost 7.43%
WACC 6.24%
Leverage 51.69%

11. Quality Control: MEI Pharma, Inc. passed 4 out of 9 key points

12.a Historical Valuation

12.b Price/Earnings Ratio

12.c Margin Valuation

12.d Peers Valuation

Peers Group Analysis

Stock-Card
Catalyst Pharmaceuticals

A-Score: 5.8/10

Value: 5.4

Growth: 9.8

Quality: 9.4

Yield: 0.0

Momentum: 5.0

Volatility: 5.0

1-Year Total Return ->

View Full Report
Stock-Card
Innoviva

A-Score: 4.7/10

Value: 4.9

Growth: 5.4

Quality: 6.6

Yield: 0.0

Momentum: 3.0

Volatility: 8.3

1-Year Total Return ->

View Full Report
Stock-Card
Spero Therapeutics

A-Score: 4.5/10

Value: 7.0

Growth: 6.2

Quality: 4.8

Yield: 0.0

Momentum: 9.0

Volatility: 0.0

1-Year Total Return ->

View Full Report
Stock-Card
MEI Pharma

A-Score: 4.5/10

Value: 7.6

Growth: 4.8

Quality: 5.2

Yield: 5.0

Momentum: 3.0

Volatility: 1.3

1-Year Total Return ->

View Full Report
Stock-Card
Armata Pharmaceuticals

A-Score: 4.4/10

Value: 8.0

Growth: 4.6

Quality: 6.1

Yield: 0.0

Momentum: 8.0

Volatility: 0.0

1-Year Total Return ->

View Full Report
Stock-Card
Heron Therapeutics

A-Score: 3.6/10

Value: 7.4

Growth: 6.2

Quality: 5.1

Yield: 0.0

Momentum: 1.0

Volatility: 1.7

1-Year Total Return ->

View Full Report

Peers Metrics

12.e Scoring Insights

12.f DCF BETA

Parameters

Short Term Growth

Short term Time

Long-Term Growth

WACC

Target Price

3.07$

Current Price

3.07$

Potential

-0.00%

Expected Cash-Flows